Detail

Paricalcitol

Description

Name: Paricalcitol
Type: small molecule
Groups: Array
Indication: For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Accession Number: DB00910 ( APRD01165)
Description: Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Paricalcitolinjection, solution2 ug/mLintravenous01-11-2014US
Paricalcitolinjection, solution5 ug/mLintravenous01-11-2014US
Paricalcitolinjection5 ug/mLintravenous18-11-2014US
Paricalcitolinjection5 ug/mLintravenous18-11-2014US
Paricalcitolinjection2 ug/mLintravenous18-11-2014US
Paricalcitolcapsule, liquid filled1 ug/1oral14-06-2010US
Paricalcitolcapsule, liquid filled2 ug/1oral14-06-2010US
Zemplarcapsule, liquid filled4 ug/1oral14-06-201029-12-2015US
Zemplarinjection, solution5 ug/mLintravenous17-04-1998US
Zemplarcapsule, liquid filled2 ug/1oral14-06-2010US
Zemplarcapsule, liquid filled1 ug/1oral14-06-2010US
Zemplarinjection, solution2 ug/mLintravenous17-04-1998US
Zemplarsolution5 mcgintravenous01-12-200503-11-2012Canada
Zemplarcapsule, liquid filled1 ug/1oral26-05-2005US

Generic Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Paricalcitolcapsule1 ug/1oral17-01-2016US
Paricalcitolcapsule2 ug/1oral17-01-2016US
Paricalcitolcapsule4 ug/1oral17-01-2016US
Paricalcitolcapsule, liquid filled1 ug/1oral14-01-2016US
Paricalcitolcapsule, liquid filled2 ug/1oral14-01-2016US
Paricalcitolcapsule, liquid filled4 ug/1oral14-01-2016US
Paricalcitolcapsule1 mg/1oral02-09-2015US
Paricalcitolcapsule2 mg/1oral01-10-2015US
Paricalcitolcapsule4 mg/1oral01-10-2015US
Paricalcitolcapsule, gelatin coated1 ug/1oral03-11-2015US
Paricalcitolcapsule, gelatin coated2 ug/1oral03-11-2015US
Paricalcitolcapsule, gelatin coated4 ug/1oral03-11-2015US
Paricalcitolcapsule, liquid filled1 ug/1oral27-03-2014US
Paricalcitolcapsule, liquid filled2 ug/1oral27-03-2014US
Paricalcitolcapsule, liquid filled4 ug/1oral27-03-2014US
Paricalcitolcapsule, liquid filled1 ug/1oral07-12-2015US
Paricalcitolcapsule, liquid filled2 ug/1oral07-12-2015US
Paricalcitolcapsule, liquid filled4 ug/1oral07-12-2015US
Paricalcitolcapsule, liquid filled1 ug/1oral31-03-2015US
Paricalcitolcapsule, liquid filled1 ug/1oral23-04-2014US
Paricalcitolcapsule, liquid filled2 ug/1oral23-04-2014US
Paricalcitolcapsule, liquid filled4 ug/1oral27-03-2014US
Paricalcitolcapsule, liquid filled1 ug/1oral25-06-2014US
Paricalcitolcapsule, liquid filled2 ug/1oral25-06-2014US
Paricalcitolcapsule, liquid filled4 ug/1oral25-06-2014US
Paricalcitolcapsule, liquid filled1 ug/1oral30-09-2013US
Paricalcitolcapsule, liquid filled2 ug/1oral30-09-2013US
Paricalcitolcapsule, liquid filled4 ug/1oral30-09-2013US

Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
ZemplarParicalcitol
ZemplarParicalcitol
ZemplarParicalcitol
ZemplarParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ZemplarParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ZemplarParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ZemplarParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol
ParicalcitolParicalcitol

Categories
  • No Category

Pharmacology

Indication: For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Pharmacodynamics: Not Available
Mechanism of action: Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.
Absorption: Well absorbed
Volume of distribution:
  • 30.8 ± 7.5 L [CKD Stage 5-HD]
  • 34.9 ± 9.5 L [CKD Stage 5-PD]
  • 23.8 L [healthy subjects]

Protein binding: 99.8% (bound to plasma proteins)
Metabolism: Not Available
Route of elimination: Paricalcitol is excreted primarily by hepatobiliary excretion.
Half life: 4 to 6 hours
Clearance: Not Available
Toxicity: Not Available
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Abbott laboratories pharmaceutical products div
  • Abbott laboratories

Packagers:
Dosage forms
FormRouteStrength
Capsuleoral1 mg/1
Capsuleoral1 ug/1
Capsuleoral2 ug/1
Capsuleoral2 mg/1
Capsuleoral4 mg/1
Capsuleoral4 ug/1
Capsule, gelatin coatedoral1 ug/1
Capsule, gelatin coatedoral2 ug/1
Capsule, gelatin coatedoral4 ug/1
Capsule, liquid filledoral4 ug/1
Injectionintravenous2 ug/mL
Injectionintravenous5 ug/mL
Capsule, liquid filledoral1 ug/1
Capsule, liquid filledoral2 ug/1
Injection, solutionintravenous2 ug/mL
Injection, solutionintravenous5 ug/mL
Solutionintravenous5 mcg

Prices
Unit descriptionCostUnit
Zemplar 1 mcg capsule$9.39capsule
Zemplar 2 mcg/ml vial$11.22ml
Zemplar 2 mcg capsule$18.79capsule
Zemplar 5 mcg/ml vial$28.03ml
Zemplar 4 mcg capsule$37.58capsule

Patents
CountryPatent NumberApprovedExpires (estimated)
5246925United States1995-04-172012-04-17
6136799United States1998-10-082018-10-08

Interactions

Drug Interactions
DrugInteraction
Aluminum hydroxideThe serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.
AtazanavirThe serum concentration of Paricalcitol can be increased when it is combined with Atazanavir.
BoceprevirThe serum concentration of Paricalcitol can be increased when it is combined with Boceprevir.
CeritinibThe serum concentration of Paricalcitol can be increased when it is combined with Ceritinib.
ClarithromycinThe serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Paricalcitol can be increased when it is combined with Cobicistat.
ColesevelamThe serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam.
DanazolDanazol may increase the hypercalcemic activities of Paricalcitol.
DarunavirThe serum concentration of Paricalcitol can be increased when it is combined with Darunavir.
DigoxinThe risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin.
DihydrotachysterolThe risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Paricalcitol.
IdelalisibThe serum concentration of Paricalcitol can be increased when it is combined with Idelalisib.
IndinavirThe serum concentration of Paricalcitol can be increased when it is combined with Indinavir.
ItraconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole.
Mineral oilThe serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil.
NefazodoneThe serum concentration of Paricalcitol can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir.
OrlistatThe serum concentration of Paricalcitol can be decreased when it is combined with Orlistat.
PosaconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Posaconazole.
RitonavirThe serum concentration of Paricalcitol can be increased when it is combined with Ritonavir.
SaquinavirThe serum concentration of Paricalcitol can be increased when it is combined with Saquinavir.
SucralfateThe serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.
TelaprevirThe serum concentration of Paricalcitol can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Paricalcitol can be increased when it is combined with Telithromycin.
TrichlormethiazideTrichlormethiazide may increase the hypercalcemic activities of Paricalcitol.
VoriconazoleThe serum concentration of Paricalcitol can be increased when it is combined with Voriconazole.

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Cyclic alcohols and derivatives
  • Cyclohexanols
  • Hydrocarbon derivatives
  • Tertiary alcohols
  • Vitamin D and derivatives

substituent:
  • Alcohol
  • Aliphatic homopolycyclic compound
  • Cyclic alcohol
  • Cyclohexanol
  • Hydrocarbon derivative
  • Organooxygen compound
  • Polycyclic triterpenoid
  • Secondary alcohol
  • Tertiary alcohol
  • Triterpenoid

References

Synthesis Reference: Anchel Schwartz, Alexei Ploutno, Koby Wolfman, "Preparation of paricalcitol." U.S. Patent US20070149489, issued June 28, 2007.
General Reference: Not Available
External Links:
ResourceLink
RxListhttp://www.rxlist.com/cgi/generic4/zemplar_caps.htm
Drugs.comhttp://www.drugs.com/cdi/paricalcitol.html

ATC Codes:
  • Array

AHFS Codes:
  • 88:16.00

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?